HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Trevi Therapeutics, maintaining a price target of $6. This suggests confidence in the company's future performance.
October 22, 2024 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Trevi Therapeutics, maintaining a price target of $6. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $6 price target by HC Wainwright & Co. indicates a positive outlook on Trevi Therapeutics. This can lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100